Brain-computer interfaces (BCIs) are commercializing rapidly in 2025.
BCIs, which interpret neural activity to enable direct communication between the brain and external systems like computers or robotic limbs, have attracted record investment this year. Funding tripled to $867M from 2024, driven largely by Neuralink‘s $650M Series E round at a $9.7B valuation.
Clinical validation is also gaining momentum, with over 70 clinical studies using BCIs currently recruiting patients. Adding to this progress, Precision Neuroscience received the first FDA clearance in March 2025 for BCI use in brain-mapping during neurosurgery, marking an early regulatory breakthrough.
